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Abstract Aims/hypothesis: Although thiazolidinediones
are now widely used to treat type 2 diabetes, their mech-
anism of action remains largely unknown. They are ago-
nists for the transcription factor PPARγ, and in addition to
their insulin-sensitising effects, they can promote adipo-
genesis and control gene expression in adipose tissues. We
have explored the effect of rosiglitazone on insulin-me-
diated induction of pivotal genes involved in lipid metab-
olism and thermogenesis in brown fat. The genes studied
were: (1) lipoprotein lipase (lpl), which is involved in lipid
uptake; (2) hormone-sensitive lipase (hsl), which mobilises
fatty acids from stored triglycerides; (3) fatty acid synthase
(fas), which regulates de novo lipogenesis; and (4) the un-
coupling proteins (ucp) 1 and 3, which control thermogen-
esis. Methods: We used fetal rat primary brown adipocytes
cultured with insulin, rosiglitazone or both combined. Then,
we studied gene expression by northern and western blot-
ting, as well as ‘run-on’ and gel-shift assays to identify bind-
ing of potential transcription factors to the fas promoter.
Results: Exposure to rosiglitazone for 24 h induced ucp-1,
lpl and hsl gene expression and when rosiglitazone was
combined with insulin a synergistic effect on lpl and ucp-3
mRNA expression was produced. These effects were con-
sistent with increased LPL and HSL activities as well as
respiration rates, mainly in response to exogenous palmi-
tate. In contrast, treatment with rosiglitazone did not alter
FAS mRNA basal levels but prevented the induction elic-
ited by insulin in a time- and dose-dependent manner. Cor-
respondingly diminished FAS protein levels and activity, as
well as cellular lipid content, were observed, indicating an
antilipogenic action of rosiglitazone in brown adipocytes.
Furthermore, rosiglitazone impaired insulin increase in the
FAS transcription rate by antagonising insulin-induced bind-
ing of upstream stimulatory factors to the E-box consensus
sequence in the FAS promoter and insulin-induced binding
of activating protein-1. Conclusions/interpretation: Rosi-
glitazone prevents insulin-induced up-regulation of the main
lipogenic enzyme but increases the expression of those en-
zymes involved in lipid uptake and mobilisation, favouring
fatty acid utilisation through uncoupled respiration.
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Abbreviations AP-1: activating protein 1 . ECL:
enhanced chemiluminescence . FAS: fatty acid synthase .
HSL: hormone-sensitive lipase . LPL: lipoprotein lipase .
PGC-1: PPARγ co-activator-1 . PPAR: peroxisome
proliferating activated receptor . SREBP: sterol regulatory
element binding protein . TZD: thiazolidinediones .
UCP: uncoupling protein . USF: upstream stimulatory factor
Introduction
Thiazolidinediones (TZDs) are insulin-sensitising drugs
that improve insulin action in vivo across a wide spectrum
of insulin-resistant states, and have recently been intro-
duced as therapeutic agents for the treatment of type 2
diabetes [1]. Although TZDs were developed without knowl-
edge of their molecular targets, they are agonists for the
nuclear receptor peroxisome proliferating activated recep-
tor (PPAR)γ, and the relative ability of different TZDs to
bind and activate PPARγ in vitro correlates with the anti-
diabetic action of these drugs in vivo [1, 2]. Moreover, PP
ARγ are ligand-activated transcription factors that play a
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critical role in the adipogenic differentiation process. Ac-
cordingly, either TZDs or ectopic expression of PPARγ
dramatically promoted adipogenic differentiation from pre-
adipocytes or non-adipogenic cells [3, 4]. Besides increas-
ing insulin sensitivity and adipogenesis, TZDs control
specific gene expression in white adipose tissue, a tissue in
which there is high expression of PPARγ. In this regard,
the TZD rosiglitazone up-regulated hormone-sensitive li-
pase (HSL) and lipoprotein lipase (LPL) gene expression
and increased insulin responsiveness in lipolysis and lipo-
genesis in human subcutaneous adipocytes [5]. Moreover,
induction of glycerol kinase gene expression by TZDs on
murine mature adipocytes has been described [6]. All these
effects have been proposed as the mechanism of action for
TZDs to reduce circulating NEFA, which cause insulin re-
sistance in skeletal muscle and other insulin target tissues.
The increase in fat mass due to LPL expression was con-
sistent with the weight gain observed in humans during
treatment with rosiglitazone [2]. Furthermore, recent stud-
ies have reported attenuated insulin resistance (due to in-
creased expression of adiponectin, PPARγ and PGC-1, and
decreased expression of IL-6) without changes in the fat
content of the subcutaneous adipose tissue from patients
with highly active antiretroviral therapy-associated lipo-
dystrophy treated with rosiglitazone [7].
Although white adipose tissue is the main adipose tissue,
brown adipose tissue is also present in small mammals.
Brown adipose tissue is specialised in non-shivering ther-
mogenesis and is responsible for the heat production as-
sociated with expression of the mitochondrial uncoupling
protein (UCP)-1 [8]. Brown adipocytes are also a target for
TZD action, since they have high expression of PPARγ;
TZDs were found to promote adipogenic and thermogenic
differentiation in these cells [9, 10]. Moreover, we have
recently shown that rosiglitazone produces insulin sensi-
tisation under physiological and insulin-resistance condi-
tions in cultured brown fat cells [11, 12]. Regarding gene
expression, rosiglitazone up-regulated ucp-1 through bind-
ing to the PPAR response element present in the enhancer
of this gene [13–15]. Fuels for thermogenesis are provided
as fatty acids, which can be obtained: (1) via uptake from
lipoproteins by the action of LPL; (2) via lipolysis from
stored triglycerides by HSL; and (3) via de novo lipid
synthesis by fatty acid synthase (FAS). Brown adipocytes
express LPL and are also responsible for prominent de
novo lipid synthesis, since glucose is an essential lipogenic
substrate and insulin one of the most potent signals in
inducing the expression of FAS [10, 16]. Therefore, this
cell model provides an ideal system for investigating reg-
ulation of the expression of pivotal genes involved in lipid
metabolism and thermogenesis by rosiglitazone and/or
insulin.
Materials and methods
Materials Insulin and BSA (fraction V, essentially NEFA-
free) were from Sigma Chemical (St. Louis, MO, USA).
Wy14643 was purchased from Biomol Research Labora-
tories (Plymouth, UK). Rosiglitazone was kindly provided
by Dr S. A. Smith (Glaxo SmithKline, Harlow, UK). Fetal
calf serum, PBS, culture media and Trizol were from In-
vitrogen (Paisley, UK). Autoradiographic films were Kodak
X-O-MAT/AR (Eastman Kodak, Rochester, NY, USA).
(α-32 P)dCTP, (α-32P)UTP and the multiprimer DNA-
labelling system kit were purchased from Amersham
Biosciences (Little Chalfont, UK). The mouse anti-FAS
antibody was from BD Biosciences Pharmingen (San
Diego, CA, USA). The antibody anti-UCP-1 was from
Alexis (Lausanne, Switzerland). The antibodies for super-
shift experiments were anti-sterol regulatory element bind-
ing protein (SREBP)1 ‘sc-8984’ from Santa Cruz (Palo
Alto, CA, USA), and anti-upstream stimulatory factor
(USF) 1 and 2 was kindly provided by Dr Viollet (Institut
Cochin de Genetique Moleculaire, Paris, France) [17]. All
other reagents used were of the purest grade available.
Cell culture Fetal brown adipocytes were obtained from
interscapular brown adipose tissue of 20-day-old Wistar rat
fetuses and isolated by collagenase dispersion as described
previously [16]. Isolated cells were plated in tissue culture
dishes (4×106 cells per 100-mm diameter dish) in minimal
essential mediumwith Earle’s salts supplemented with 10%
fetal calf serum, the presence of serum being essential for
the cells to attach to the plastic surface of the dishes. After
4–6 h of culture at 37°C, cells were rinsed twice with PBS
and a 70% confluent monolayer was observed under in-
verse light microscopy. Cells were maintained for 20 h in a
serum-free medium supplemented with 0.2% (w/v) BSA
and then cultured for different times (from 3 to 48 h) with or
without insulin (10 nmol/l), rosiglitazone (10 μmol/l) or
Wy14643 (10 μmol/l) alone or in combination. Wistar rats
were obtained from the Complutense University Animal
House (Madrid, Spain). The principles of laboratory animal
care were followed and the study was approved by the local
ethics committee and carried out in accordance with the
Declaration of Helsinki.
Northern blotting RNA was isolated and submitted to
northern blot analysis as described previously [14]. For
serial hybridisation with different probes, such as FAS, LPL,
HSL, UCP-1 and UCP-3 cDNAs, the blots were stripped
and then rehybridised as needed in each case. A final hy-
bridisation with the 18 S rRNA cDNA was performed for
normalisation. The membranes were subjected to autora-
diography and the relative densities of the hybridisation
signals were measured by densitometric scanning of the au-
toradiograms in a laser densitometer (Molecular Dynamics,
Sunnyvale, CA, USA).
Western blotting Proteins were isolated and submitted to
western blot analysis as described previously [11]. Im-
munoreactive bands were visualised using the enhanced
chemiluminescence (ECL-Plus) western blotting protocol
(Amersham).
Brown adipocyte respiration After different treatments,
cells were detached from the plates and suspended at 4×105
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cells/ml in PBS containing 5 mmol/l pyruvate, 10 mmol/l
D-glucose, 10 mmol/l fructose and 32 μmol/l BSA, pH 7.4,
37°C, in a Hansa-Tech oxygen electrode chamber [18].
Other additions are described in the figure legends.
FAS activity Cells were sonicated for 30 s at 1.5 mA in
0.1 mmol/l EDTA, 1 mmol/l dithiothreitol, 1 mm/l MgCl2,
10% (v/v) glycerol, 0.1 mmol/l NaH2P04 (pH 7.2), and
centrifuged at 12,000×g for 4 min. The cytosolic superna-
tant was used for the spectrophotometric determination of
FAS activity, as described previously [19]. Enzyme activity
was expressed as nanomoles of NADPH consumed per
minute per milligram of protein.
LPL activity Cellular pellets were homogenised in 0.2 mol/l
Tris-HCl (pH 8.2) at 4°C and delipidated with acetone–
diethyl ether as described previously [20]. LPL activity was
assayed in triplicate using an egg lecithin-stabilised emul-
sion of 14C-fatty acid-labelled triolein as substrate contain-
ing: 2.5 mmol/l triolein, 2.4%BSA, 0.2 mol/l Tris, 0.1 mol/l
NaCl, and 0.8% heated rat serum (pH 8.2), in the absence
or presence of 1 mol/l NaCl (high saline concentrations).
LPL activity was determined by subtracting the non-LPL-
dependent activity (high salt) from the total lipolytic
activity.
HSL activity Cellular pellets were homogenised in three
volumes of 0.25 mol/l sucrose containing 1 mmol/l EDTA,
1 mmol/l dithiothreitol, 10 μg/ml antipain (pH 7.4) as de-
scribed previously [20]. Infranatants were obtained by cen-
trifugation at 110,000×g in a Beckman centrifuge (model
TL-100) for 45 min at 4°C. A phospholipid-stabilised emul-
sion of a dioleoylglycerol ether analogue, 1(3)-mono[3H]
oleyl-2-O-oleoylglycerol, was used to assay the hormone-
sensitive diacylglycerol lipase activity. Inhibition experiments
were performed by pre-incubation with 100 mmol/ l NaF.
Lipid content Cytoplasmic lipid content was determined by
Nile Red fluorescence emission in a FACScan flow cyto-
meter (Becton Dickinson, Franklin Lakes, NJ, USA) as
described previously [16]. Results represent mean inten-
sities of fluorescence, obtained from the histograms of
Fig. 1 Rosiglitazone induces UCP-1 expression and respiration in
brown adipocytes. Brown adipocytes were serum-deprived for 20 h
and further cultured for 24 h in the absence (control, C) or presence of
10 nmol/l insulin (I), 10 μmol/l rosiglitazone (R) or both (IR). a Total
RNAwas submitted to northern blotting with labelled UCP-1, UCP-3
and 18 S rRNA cDNAs. b Total protein was submitted to western
blotting with anti-UCP-1 antibody and developed with ECL. Rep-
resentative autoradiograms out of four are shown. Histograms from
densitometric analysis of the autoradiograms are expressed in
arbitrary units and represent means±SEM (n=4). *p<0.05 and
***p<0.001 for differences vs C; ♦ p<0.05 for differences in the
presence of (IR) vs (R). c Traces of the respiration of cells after the
following additions were made: 2.5 μg/ml oligomycin (Oligo);
64 μmol/l palmitate (Palm) (2:1 molar ratio to albumin); and
10 μmol/l FCCP. Rates are expressed in nanomoles of O2 consumed
per minute and per 106 cells. A representative experiment of four
independent experiments is shown
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number of cells vs intensity of fluorescence, and are ex-
pressed in arbitrary units.
Nuclear run-on transcription assay Nuclei were prepared
and the run-on transcription assay was performed using
(α-32P)UTP following the protocol described previously
[16]. The incorporation of (α-32P)UTP into RNA was de-
termined by scintillation counting, and equal counts were
hybridised to filter-immobilised plasmids as described for
northern blotting. Quantification of the signals was per-
formed by densitometric scanning of the slots and signals
were standardised using the β-actin signal.
Gel-shift assay Nuclear extracts were prepared and in-
cubated with labelled oligonucleotides following the gel
mobility shift assay described previously [21]. The double-
stranded oligonucleotide used as the AP-1 probe was com-
posed of the sequence 5′-AGCTTGATGAGTCAGGGG
CCGGATC-3′, and for the −65-bp E-box of the FAS pro-
moter the sequence used was 5′-AGCTGTCAGCCCAT
GTGGCGTGGCCGC-3′. The AP-1 and E-box double-
stranded oligonucleotides were chemically synthesised by
Sigma-Genosys (Haverhill, UK). Oligonucleotides were
labelled using Klenow polymerase and (α-32P)dCTP. The
binding reaction was performed at 4°C for 15 min in a
buffer containing 0.5 ng of doubled-stranded oligonucle-
otide probe, 2 μg of poly(dIdC), and 10 μg of protein in
buffer C, supplemented with 35 mmol/l MgCl2. For su-
pershift and competition assays, nuclear extracts were
previously incubated for 15 min at 4°C with 1 μl of the
corresponding antibodies or 100-fold excess of cold probe.
DNA–protein complexes were resolved on a 6% polyacryl-
amide gel. The gel was dried and exposed to film at −70°C.
Data analysis Results are presented as means±SEM (n=4)
for duplicate dishes from four independent experiments.
Statistical significance was tested with ANOVA, followed
by the protected least-significant different test. A p value of
less than 0.05 was considered significant. In experiments
using X-ray films (Hyperfim), different exposure times
were used to ensure that bands were not saturated.
Results
Rosiglitazone up-regulates the expression of UCP-1, UCP-3,
LPL and HSL in brown adipocytes Rat fetal brown adi-
pocytes were maintained for 20 h in a serum-free medium
and further cultured for 24 h in the absence or presence of
rosiglitazone (10 μmol/l) or insulin (10 nmol/l), individu-
Fig. 2 Rosiglitazone up-regulates the expression of LPL and HSL.
Cells were cultured as in Fig. 1. a Total RNA was analysed by
northern blotting with labelled LPL and 18 S rRNA cDNAs. A
representative example of four autoradiograms is shown. Histograms
from densitometric analysis represent means±SEM (n=4). b LPL
activity was measured in cellular homogenates and was expressed as
picokatals per milligram of protein (picokatals, picomoles of sub-
strate transformed per second). Results are shown as means±SEM
(n=4). *p<0.05 and ***p<0.001 for differences vs control (C); ♦
p<0.001 for differences between values in the presence of IR vs I and
vs R. c Total RNA was analysed by northern blotting with labelled
HSL and 18 S rRNA cDNAs. d Total protein was submitted to
western blotting with antibodies against HSL or against β-actin and
developed with ECL. A representative example of four autoradio-
grams is shown. e HSL activity in cellular homogenates was mea-
sured as described in Materials and methods and is expressed as
milliunits per milligram protein. Results are expressed as means±
SEM (n=4). ***p<0.05 for differences vs control (C); Δp<0.05 for
differences between values in the presence of I vs its absence
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ally or combined. The expression of the thermogenic genes
ucp-1 and ucp-3 was studied by northern and western
blotting, respectively (Fig. 1). Rosiglitazone significantly
increased UCP-1 mRNA and protein levels (5-fold), insulin
caused a 50% increase in these levels, and the combined
presence of insulin and rosiglitazone produced a lower
effect (4-fold) than rosiglitazone alone (Fig. 1a, b). The
UCP-3 mRNA accumulation induced by rosiglitazone or
insulin individually increased 2-fold but the result was
additive when both compounds were combined (Fig. 1a). In
order to determine whether changes in UCP expression
were associated with changes in the thermogenic capacity
of the cells, respiratory rates were calculated. As shown in
Fig. 1c, the basal respiratory rates showed a good cor-
relation with the UCP-1 levels in all the treatments studied.
However, the most striking feature was the stimulation of
respiration by exogenous palmitate, which should activate
UCP-1 in situ. In the presence of oligomycin (absence of
ATP synthesis), palmitate increased respiration by 36% in
insulin-treated cells, by 148% in cells stimulated with
rosiglitazone, and by 86% under both treatments.
Since rosiglitazone appeared to induce UCP-1 expres-
sion and respiration rates in brown adipocytes, we inves-
tigated the possibility that it might enhance the availability
of NEFA for oxidation. In consequence, we studied LPL
and HSL gene expression under identical culture conditions
as described above. As shown by northern blot analysis in
Fig. 2a, the presence of either insulin or rosiglitazone
Fig. 3 Rosiglitazone down-regulates insulin-induced FAS gene
expression in a dose- and time-dependent manner, and also down-
regulates cellular lipid content. Brown adipocytes were serum-
deprived for 20 h and further cultured for 24 h in the absence (control,
C) or presence of 10 nmol/l insulin (I) or 10 μmol/l rosiglitazone (R)
or 10 μmol/l Wy14643 (Wy) alone or in combination (a); or with
insulin with or without increasing concentrations of rosiglitazone (b);
or for 6, 24 or 48 h in the absence or presence of insulin with or
without rosiglitazone (c). Total RNAwas extracted under the different
conditions and submitted to northern blotting with labelled probes. A
representative of four autoradiograms is shown. Densitometric
analysis of FAS mRNA levels after standardisation using the 18 S
rRNA signal is shown. Results (arbitrary densitometric units) are
presented as means±SEM (n=4). d Cells were cultured for 48 h as in
Fig. 1. Total protein was submitted to western blotting with anti-FAS
antibody and developed with ECL. A representative example of four
autoradiograms is shown. Histograms represent means±SEM (n=4).
e Cell extracts were used to determine FAS activity. Results are
shown as means±SEM (n=4) and are expressed as nanomoles of
NADPH used per minute per milligram of protein. f Cytoplasmic
lipid content was determined by Nile Red fluorescence as described
in Materials and methods. Results (arbitrary densitometric units) are
expressed as means±SEM (n=4). *p<0.05 and ***p<0.001 for dif-
ferences between values in the presence of I vs control (C); Δp<
0.001 for differences between values in the presence of IR vs I
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doubled the LPL mRNA content; this effect was higher (5-
fold) when both compounds were added together. Lower
doses of rosiglitazone also had a synergistic effect with
insulin on LPLmRNA accumulation (Fig. 3b). LPL activity
was also measured in lysates from cells treated as described
above. Both insulin and rosiglitazone individually had a
positive effect on LPL activity, and combined produced an
additive effect on LPL activity (Fig. 2b), in a similar fashion
to mRNA accumulation. Rosiglitazone doubled HSL mR
NA and protein content regardless of the absence or pres-
ence of insulin (Fig. 2c, d). Moreover, rosiglitazone in-
creased HSL activity by 2-fold; this effect was partially
precluded when insulin was present in the culture medium
(Fig. 2e).
Rosiglitazone impairs insulin-induced FAS gene expression
by antagonising the binding of insulin-induced USFs to the
FAS promoter and insulin-induced AP-1 binding activity
Fatty acids can be synthesised de novo by the lipogenic
enzyme FAS. In this regard, treatment for 24 h with insulin,
a potent lipogenic signal, produced a significant 9-fold)
FAS mRNA accumulation compared with untreated cells
(Fig. 3a). However, rosiglitazone alone failed to have any
positive effect on FAS mRNA accumulation and, surpris-
ingly, significantly decreased the response to insulin. In
contrast to the effect of rosiglitazone, the PPARα agonist
Wy14643 (10 μmol/l) did not alter the insulin effect on FAS
mRNA levels. To further explore the mechanisms for the
inhibition of insulin-induced FAS gene expression by ro-
siglitazone, we carried out dose-response and time-course
experiments. When insulin-treated brown adipocytes were
incubated in the presence of various doses of this com-
pound, the insulin-induced increase in FAS mRNA ac-
cumulation was precluded in a concentration-dependent
manner (Fig. 3b). The expression of FAS was detectable
after 6 h of treatment with insulin, reaching maximal values
at 24 h which were maintained for 48 h. The presence of
rosiglitazone inhibited this insulin effect at all the time
points studied (Fig. 3c). Rosiglitazone not only precluded
an insulin-induced increase in FAS mRNA accumulation,
but also impaired insulin induction of FAS protein content
in cells after treatment for 48 h as determined by western
blot analysis (Fig. 3d). Accordingly, insulin stimulated FAS
activity after 48 h of treatment, but rosiglitazone totally
Fig. 4 Rosiglitazone impairs insulin-induced FAS transcription by
antagonising insulin-induced USFs binding to the FAS promoter and
insulin-induced AP-1 binding activity. Cells were treated for 3 h (a) or
24 h (b, c) as in Fig. 1. Nuclei (a) were prepared and used for a run-on
transcription assay as described in Materials and methods. Repre-
sentative autoradiograms of labelled transcripts representing FAS,
β-actin and the vector PUC12 are shown in addition to histograms
from the densitometric analysis after standardisation with the β-
actin signal. b Nuclear extracts were incubated with labelled dou-
bled-stranded oligonucleotide corresponding to the −65-bp E-box of
the FAS promoter used as the probe. Some reactions included
15 min of previous incubation with USF or SREBP antibodies or a
100-fold molar excess of unlabelled probe used as a competitor
(Comp), with the specific band that disappeared marked by an
arrow. c Nuclear extracts were subjected to electrophoretic mobility
shift assay using an AP-1 consensus site-labelled probe. A repre-
sentative example of four autoradiograms is shown. Histograms
from densitometric analysis are expressed in arbitrary units and
represent means±SEM (n=4). Statistical significance, see Fig. 3
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precluded the increase elicited by insulin at this time
(Fig. 3e). In consequence, the increase in cytoplasmic lipid
content produced by treatment with insulin for 48 h and
detected by Nile Red fluorescence was reduced by the
presence of rosiglitazone (Fig. 3f).
Since TZDs are insulin sensitisers, the striking effect of
rosiglitazone, i.e. antagonising insulin action on FAS
expression, prompted us to investigate this phenomenon
further. Accordingly, nuclear ‘run-on’ assays were per-
formed in transcriptionally active nuclei isolated from cells
treated for 3 h in the absence or presence of insulin or
rosiglitazone or both combined (Fig. 4a). The transcription
rate of the FAS gene increased 5-fold under insulin treat-
ment relative to untreated cells. Rosiglitazone alone did not
produce any effect, but significantly reduced the insulin
induction of FAS transcription (Fig. 4a). We considered the
possibility that the inhibitory effect of rosiglitazone on
insulin-induced FAS gene expression could be mediated by
interfering with transcription factors needed for insulin
action. In this regard, the promoter region of the FAS gene
contains a proximal insulin response sequence contain-
ing an E-box motif at the position −65 bp, a potential
binding site for two transcription factors: USFs and SREBP
[22–24]. We carried out electrophoretic mobility shift
assays with a labelled oligonucleotide corresponding to the
−65-bp E-box sequence and were able to observe an
increase in specific protein–DNA complexes in extracts
from insulin-stimulated cells, which was abolished in cells
co-treated with rosiglitazone (Fig. 4b). This band disap-
peared in competition experiments with unlabelled probe.
Specific antibodies against USFs but not against SREBP
eliminated most of the binding to the E-box sequence.
Furthermore, the promoter region of FAS has been reported
to possess an inverted CCAAT box at positions −106 to
−85 bp, a potential sequence for binding the transcription
factor AP-1, a factor that was activated by insulin in brown
adipocytes [25, 26]. We therefore carried out electropho-
retic mobility shift assays with oligonucleotide probes cor-
responding to the AP-1 consensus sites in nuclear extracts
from cells cultured for 24 h either in the absence or presence
of insulin, rosiglitazone or both combined (Fig. 4c). Insulin
treatment doubled nuclear protein binding to DNA corre-
sponding to the AP-1 consensus site as compared to un-
treated cells. However, rosiglitazone treatment completely
impaired insulin-enhanced AP-1 DNA binding activity
(Fig. 4c).
Discussion
In this paper we investigated the role of rosiglitazone on
insulin-mediated induction of pivotal genes involved in
lipid metabolism and thermogenesis in primary cultures of
rat fetal brown adipocytes. Our results show that insulin
produces a small induction of UCP-1 and UCP-3 expres-
sion while rosiglitazone induction of both UCPs, mainly
UCP-1, is robust and seems to be directly due to the pres-
ence of the PPAR response element present in their pro-
moters [13–15]. The concentration of rosiglitazone used in
our experiments was 10 μmol/l, the optimal dose deter-
mined in previous studies for use in brown adipocytes [13],
and close to the peak plasma concentration reached in hu-
mans, 2 μmol/l, after oral administration at the doses used
in clinical practice [27]. The positive effect of insulin on
UCP-3 gene expression observed in brown adipocytes is
in contrast to the inhibitory effect described in skeletal
muscle, indicating tissue-specific regulation of this gene
[28]. Moreover, rosiglitazone also increases basal respira-
tion rates and uncoupled respiration in response to palmi-
tate, which clearly indicates that UCP-1 is functional and
that rosiglitazone induces thermogenesis in these cells. Re-
spiratory rates may appear low when compared to those
observed in mature brown adipocytes [18], but a low respi-
ratory capacity is characteristic of immature adipocytes [29].
In parallel with UCP-1, rosiglitazone induces LPL ex-
pression in brown adipocytes, in agreement with the PPAR
response element found in the human LPL promoter [30].
When combined with insulin, rosiglitazone produces a
synergistic effect on LPL mRNA accumulation and enzy-
matic activity, as found in brown adipose tissue of rats
treated with a non-TZD PPARγ agonist [31]. These results
suggest a likely increase in NEFA uptake from lipoproteins
in response to insulin and/or rosiglitazone, in a manner
similar to that detected in human subcutaneous adipocytes
[5]. Brown adipocytes treated with rosiglitazone showed an
increased basal respiration rate and LPL activity although
they were cultured in serum-free medium with no lipopro-
tein availability. This would imply that rosiglitazone in-
duces the mechanism necessary for obtaining NEFA as fuel
for thermogenesis from lipoproteins, although under our
experimental conditions NEFA probably originated from
the hydrolysis of stored triglycerides through the activation
of HSL. With regard to this possibility, we observed an
induction of HSL mRNA and protein accumulation, re-
sulting in increased HSL enzymatic activity in the presence
of rosiglitazone, in agreement with reported data on human
adipose tissue [5]. However, insulin exerts its antilipolytic
action on HSL activity in the presence of rosiglitazone,
probably by affecting the phosphorylation of the enzyme
which is necessary for its full activation [32].
Lipid synthesis in murine adipocytes is largely a con-
sequence of de novo fatty acid synthesis from glucose,
although this metabolic pathway is minimal or absent in
humans, as recently reported [33]. Previous findings have
shown that insulin is a potent activator of the transcription
of the lipogenic gene FAS in brown adipocytes [16] as well
as in 3T3-L1 adipocytes [22, 24]. In the present study, we
describe for the first time the negative regulation by rosi-
glitazone of the insulin-mediated induction of FAS mRNA,
protein, activity and lipid content in brown adipocytes.
This inhibition seems to be a transcriptionally mediated
event, as indicated by the ‘run-on’ experiments, and de-
pendent on PPARγ activation since the PPARα agonist
Wy14643 does not behave in the same way. Dose-response
experiments with rosiglitazone indicated that half-maximal
inhibition occurred at a concentration similar to the Kd for
PPARγ, 40 nmol/l, which supports the hypothesis of a
PPARγ-mediated mechanism [34]. Our results are in agree-
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ment with the inhibitory effect of troglitazone (1 μmol/l) on
insulin-induced FAS expression reported in 3T3-L1 adipo-
cytes [35].
The fact that rosiglitazone does not produce any effect,
either positive or negative, on FAS basal expression, and
that so far there is no evidence of the presence of a PPAR
response element in the FAS promoter, suggests that direct
binding of PPARγ to the promoter is not involved in the
inhibitory mechanism, and competition for limiting amounts
of general co-activators could be the explanation. As a matter
of fact, rosiglitazone per se does not modify protein–DNA
complexes bound to E-box or AP-1 sequences but prevents
insulin-induced binding. This mechanism, known as trans-
repression, has been related to some anti-inflammatory and
anti-proliferative actions of PPARγ agonists. Thus, PPARγ
ligands blocked PMA-mediated induction of the cox-2
promoter by inhibiting AP-1 activity as a consequence of
the inhibition of c-JUN expression and competition for
limiting amounts of the general co-activator p300/CBP
[36]. Competition for the same co-activator was involved
in the inhibition of transcription of genes induced by
interferon-γ and/or lipopolysaccharide, including induc-
ible NO synthase gene [37] and also in cyclin D1 re-
pression by PPARγ [38]. Recently, rosiglitazone has also
been shown to prevent the binding of transcription factors
of the fos/jun family to the AP-1 site by inhibition of jun
kinase in heart, resulting in protection from ischaemia [39].
Therefore, the mechanism for transcriptional repression
by PPARs is either competition for limiting amounts of
general co-activators or direct inhibition of the transcription
factors that bind to response elements. We found that
rosiglitazone inhibits AP-1 binding activity induced by
insulin in brown adipocytes, and although the implication
of this transcription factor for FAS gene expression has not
been documented, the presence of an inverted CCAAT box
in the −106 to −85-bp section of the FAS promoter has been
reported [25]. Moreover, it has been reported that insulin
activates the FAS promoter through the proximal insulin-
response sequence containing an E-box motif at the −65-bp
position [22]. We found that insulin induces protein binding
to that sequence and supershift analysis has demonstrated
that USFs are the proteins bound. Therefore, we have
shown that rosiglitazone precludes insulin-induced USF
protein binding to specific sequences in the FAS promoter,
and that this correlates with the inhibition observed in FAS
mRNA and protein accumulation. USFs have been reported
to interact with PGC-1 [40, 41] and with CBP/p300 [42,
43], co-activators for many nuclear receptors including
PPARγ [44, 45]. Competition between USFs and PPARγ
for the same co-activator, for which PPARγ bound to ro-
siglitazone would have a higher affinity, is a possibility to
explore in the future.
Our results on TZD amelioration of the insulin effects on
brown adipose tissue fat content in rodents differ from
those regarding weight gain due to an increase in white
adipose tissue mass detected in humans during rosiglita-
zone therapy [2]. These effects, however, are less prom-
inent in rodents, and so far no changes in brown adipose
tissue adiposity in humans have been reported. Moreover,
no changes in fat content but attenuation of insulin re-
sistance were observed after treatment with rosiglitazone in
patients with highly active antiretroviral therapy-associated
lipodystrophy [7]. Furthermore, fat hypertrophy was de-
tected in adipose-specific PPARγ knock-out mice which
also exhibit fat cell loss [46]. Nevertheless, the actions of
rosiglitazone in vivo, such as decreasing circulating NEFA
and increasing glucose utilisation in skeletal muscle, may
be the result of the insulin-sensitising effect observed in
response to the primary action of TZDs on white adipose
tissue and brown adipose tissue. Therefore, the antagonistic
effects of rosiglitazone on insulin action—including (1)
impairment of FAS expression and lipid accumulation in
brown adipocytes together with (2) the increment in the
uptake and mobilisation of lipids through the expression
and activation of LPL and HSL and (3) the effective waste
of energy as a result of the induction of UCPs and oxidation
of NEFA in these cells—would result in a decrease in the
levels of circulating NEFA and contribute to the alleviation
of insulin resistance.
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